Xinwei Yun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xinwei Yun has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Dapeng Li
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
21 shared publications - Ming Gao
Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China
21 shared publications - Xiangqian Zheng
Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China
21 shared publications - Anqi Jin
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
20 shared publications - Ben Ma
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
20 shared publications - Biyun Qian
Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China
20 shared publications
Latest Publications
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
The difference of TIME and prognosis between molecular subtypes in the external validation set 1.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
The difference of TIME and prognosis between molecular subtypes in the external validation set 1.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Comparison of immunohistochemical index for the internal validation set 2 patients with different DLRI risk groups.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Comparison of immunohistochemical index for the internal validation set 2 patients with different DLRI risk groups.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Data from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Purpose:From 8% to 28% of patients with papillary thyroid carcinoma (PTC) experience recurrence, complicating risk stratification and treatment. We previously identified an inflammatory molecular subtype of PTC associated with poor prognosis. Based on this subtype, we aimed to develop and validate a noninvasive radiomic signature to predict prognosis and treatment response in patients with PTC.Experimental Design:We collected preoperative ultrasound images from two large independent centers (n = 2,506) to develop and validate a deep learning radiomics signature of inflammation (DLRI) for predicting the inflammatory subtype of PTC, including its correlation with prognosis and anti-inflammatory traditional Chinese medicine (TCM) treatment. Training set 1 (n = 64) and internal validation set 2 (n = 1,108) were from Tianjin Medical University Cancer Institute and Hospital. External validation sets 1 (n = 76) and 2 (n = 1,258) were from Fudan University Shanghai Cancer Center.Results:We developed a DLRI to accurately predict PTC’s inflammatory subtype (AUC = 0.97 in training set 1 and AUC = 0.82 in external validation set 1). High-risk DLRI was significantly associated with poor disease-free survival in the first cohort [HR = 16.49, 95% confidence interval (CI), 7.92–34.35, P < 0.001] and second cohort (HR = 5.42, 95% CI, 3.67–8.02, P < 0.001). The DLRI independently predicted disease-free survival, irrespective of clinicopathologic variables (P < 0.001 for all). Furthermore, patients with high-risk DLRI were likely to benefit from anti-inflammatory TCM treatment (HR = 0.19, 95% CI, 0.06–0.55, P = 0.002), whereas those with low-risk DLRI did not.Conclusions:DLRI is a reliable noninvasive tool for evaluating prognosis and guiding anti-inflammatory TCM treatment in patients with PTC. Prospective studies are needed to confirm these findings.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Purpose:From 8% to 28% of patients with papillary thyroid carcinoma (PTC) experience recurrence, complicating risk stratification and treatment. We previously identified an inflammatory molecular subtype of PTC associated with poor prognosis. Based on this subtype, we aimed to develop and validate a noninvasive radiomic signature to predict prognosis and treatment response in patients with PTC.Experimental Design:We collected preoperative ultrasound images from two large independent centers (n = 2,506) to develop and validate a deep learning radiomics signature of inflammation (DLRI) for predicting the inflammatory subtype of PTC, including its correlation with prognosis and anti-inflammatory traditional Chinese medicine (TCM) treatment. Training set 1 (n = 64) and internal validation set 2 (n = 1,108) were from Tianjin Medical University Cancer Institute and Hospital. External validation sets 1 (n = 76) and 2 (n = 1,258) were from Fudan University Shanghai Cancer Center.Results:We developed a DLRI to accurately predict PTC’s inflammatory subtype (AUC = 0.97 in training set 1 and AUC = 0.82 in external validation set 1). High-risk DLRI was significantly associated with poor disease-free survival in the first cohort [HR = 16.49, 95% confidence interval (CI), 7.92–34.35, P < 0.001] and second cohort (HR = 5.42, 95% CI, 3.67–8.02, P < 0.001). The DLRI independently predicted disease-free survival, irrespective of clinicopathologic variables (P < 0.001 for all). Furthermore, patients with high-risk DLRI were likely to benefit from anti-inflammatory TCM treatment (HR = 0.19, 95% CI, 0.06–0.55, P = 0.002), whereas those with low-risk DLRI did not.Conclusions:DLRI is a reliable noninvasive tool for evaluating prognosis and guiding anti-inflammatory TCM treatment in patients with PTC. Prospective studies are needed to confirm these findings.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Comparison of clinical characteristics for the external validation set 2 patients with different DLRI risk groups.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Comparison of clinical characteristics for the external validation set 2 patients with different DLRI risk groups.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure s5 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Perform image testing for web applications to ensure their proper functionality.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure s5 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Perform image testing for web applications to ensure their proper functionality.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Net reclassification index and integrated discrimination improvement statistics in the internal validation set 2.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Net reclassification index and integrated discrimination improvement statistics in the internal validation set 2.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
The specific operational diagrams for the website's predictive classification results.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
The specific operational diagrams for the website's predictive classification results.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Subgroup analysis of the association between DLRI risk groups and disease-free survival in other clinical characteristics in the external validation set 2.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Subgroup analysis of the association between DLRI risk groups and disease-free survival in other clinical characteristics in the external validation set 2.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Deep learning radiomic feature selection and the establishment of DLRS using the LASSO Cox regression model.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Deep learning radiomic feature selection and the establishment of DLRS using the LASSO Cox regression model.